UNILIFE MEDICAL SOLUTION (157063 / UNIFF )

http://biomedreports.com/articles/most-popular/...tract-syringes.html

**************************************************

Analyst Reports

http://www.unilife.com/...tent&task=view&id=521&Itemid=78

Griffin Securities Initiation Report
19 August 2009
REPORT: http://www.unilife.com//...om_docman&task=doc_download&gid=56

&

Unilife : Griffin Initiates at Buy, US$3 Target

(UNI.AX) (UNIFF.PK)
Written by Mike Havrilla
Thursday, 20 August 2009 04:43
http://biomedreports.com/articles/most-popular/...buy-us3-target.html

The BioMedReports.com stock research section has been updated today with a research report for Unilife Medical Solutions (UNI.AX) (UNIFF.PK) written by Keith A. Markey, PhD, of Griffin Securities on 8/19/09 with a buy rating and $3 (U.S. Dollar) price target in addition to the most recent corporate presentation for the Company from 8/13/09.


Highlights from the report include the following:

1.) Unilife has a disruptive drug delivery technology with a sound strategy to enter the U.S. and European needle and syringe markets

2.) Unilife has a big pharma partner in Sanofi-Aventis (NYSE:SNY), which is investing $38 million into the Company through an industrialization agreement

3.) Starting next year, additional supply agreements in other therapeutic areas (outside of the SNY agreement) are anticipated

4.) Unilife expects to obtain a U.S. listing for its stock, since it has relocated its headquarters to Pennsylvania and also has a major manufacturing facility there

                                      (Anmerkung: US$3 Target within next 12 month)

**************************************************

AGM Presentation  by the CEO

http://www.unilife.com//...B_iframe=true&width=610&height=365

&

Unilife Medical Solutions Chairman's Letter to Shareholders

Tuesday August 18, 2009, 11:38 am EDT
http://finance.yahoo.com/news/...tions-iw-124254092.html?x=0&.v=1

**************************************************

Thread-Eröffnung (22.08.2009)
Kurs 21.08.09 Berlin   : 0,407€
Kurs 21.08.08 OTCBB : 0,620$

**************************************************

...weitere Informationen zu finden hier: http://investorshub.advfn.com/boards/board.aspx?board_id=15924

in diesem Sinne 0815ax

Key Business Relationships

www.unilife.com/...ntent&task=view&id=17&Itemid=34

- Sanofi-aventis
en.sanofi-aventis.com/

- West Pharmaceutical Services
west%20pharmaceutical%20services%20www.westpharma.com%20/

- Tessy Plastics
www.www.tessy.com/

- Shanghai Kindly Enterprise Development Group Limited (KDL)
www.kdlchina.com/

Document Size:  12 pages
Price:  $20

reports.finance.yahoo.com/w0?r=32383554:1

Document Size:  27 pages
Price:  --

www.unilife.com//...om_docman&task=doc_download&gid=56

Near-Term Milestones (Page 5/27 - Analyst Report)

REPORT: www.unilife.com//index.php


CORPORATE HISTORY

...
Oct./08 - Received FDA certification of the Unitract 1ml syringe via 510k application
Jan./09 - Consolidated operations in the United States
June/09 - Entered into industrialization agreement with sanofi-aventis for ready-to-fill syringes


NEAR-TERM-MILESTONES

Q3/09 - Locate a site for a new manufacturing plant in Pennsylvania
Q3/09 - Sign sourcing agreement for an automated manufacturing line (60 million units/year)
Q4/09 - Complete exclusivity list discussions with sanofi-aventis for certain drug classes
Q4/09 - List Unilife Medical Solutions stock an a major U.S. stock market
Q4/09 - Launch Unitract 1ml syringe in the United States and Europe
Q2/10 - Sign a ready-to-fill syringe supply agreement with a second drug company
H1/10 - Raise funds via an equity offering to help finance manufacturing equipment, inventory, and possibly a small acquisition
Q3/10 - Order equipment for first high-volume (150 million units/year) manufacturing line
H2/10 - Move in new manufacturing plant
Q4/10 - Complete work under the industrialization agreement for the ready-to-fill syringe
Q4/11 - Begin commercial shipments of ready-to-fill syringes to sanofi-aventis

Quarterly Report for the Period Ending 30 June 2009 and Appendix 4C

04 August 2009
www.unilife.com/...tent&task=view&id=517&Itemid=77

...
Cash Reserves

During the quarter, receipts from customers of Unilife and its US subsidiary were $5.4 million. Net operating cash outflow for Unilife and its US subsidiary was $0.5 million. Unilife invested approximately $2.0 million in research and development and the purchase of plant and equipment. Unilife had cash reserves of $4.7 million as at 30 June 2009.

Details of Unilife’s cash flow are set out in the attached Appendix 4C.
www.unilife.com//...om_docman&task=doc_download&gid=52

ih.advfn.com/...s=NO%5EUNIFF&p=0&t=20&showctype=1" style="max-width:560px" />

ih.advfn.com/...s=NO%5EUNIFF&p=5&t=20&showctype=1" style="max-width:560px" />

Unilife Medical Solutions @ Rodman & Renshaw Annual Global Investment Conference

11th Annual Healthcare Conference
September 9-11,2009 New York Palace Hotel - New York, NY
www.rodmanandrenshaw.com/conferences

2009-09-10 // Henry Salon (5th Floor)
04:30 PM Unilife Medical Solutions Limited (ASX: UNI AU)

Unilife to Exhibit at Two Major Pharmaceutical Industry Events

Oct 21, 2009 10:04 ET
www.marketwire.com/press-release/...ution-ASX-UNI-1063118.html

wotnews.com.au/announcement/...orm_10_in_USA_with_SEC/1011184/

...The Directors of Unilife Australia are pleased to confirm that the process for the NASDAQ listing has now commenced by way of filing a Form 10 registration statement for review by the US Securities and Exchange Commission (SEC), a precursor to applying for the NASDAQ listing. The Form 10 is available on the SEC's website at: www.sec.gov/cgi-bin/...01476170&owner=exclude&count=40 ...

Unilife Medical (ASX: UNI.AX) (UNIFF.PK): Recent Sell-Off Unwarranted, Quick Rebound Likely

Written by Mike Havrilla
Sunday, 13 December 2009 13:14
biomedreports.com/articles/most-popular/...rebound-likely.html

"During this transition  period, which will result in Unilife Corporation becoming the trading  entity for the Unilife Group, shareholders will need to be conscious of  upcoming changes to our ticker codes. On 18 January 2010, our ASX code  will change from 'UNI' to 'UNS' and Unilife Corporation CDIs will  commence trading on ASX on a deferred settlement basis. From 2 February  2010, CDI trading should commence on a normal T+3 settlement basis.
 
"For those shareholders electing to retain their Unilife shares  on the ASX as CDIs, there will be little apparent change apart from our  Australian ticker code. Shareholders choosing to transfer their holdings  to shares of Unilife Corporation common stock that will be tradeable on  NASDAQ (subject to the application to list on NASDAQ being approved)  will have their shares consolidated on a six to one basis. Following the  NASDAQ listing, should shareholders wish to trade their shares of  Unilife Corporation common stock, they may choose to either convert it  back to CDIs or appoint a qualified broker with the capacity to trade in  Unilife Corporation common stock on NASDAQ on their behalf."
 
 Timetable to implementation
 
The Company would also like to  take this opportunity to set out the timetable for completion of the  redomiciliation:
 
Event                                                     Date
 --------------------------------------------------    -----------------
Federal Court hearing for approval of the Schemes          14 January 2010
 --------------------------------------------------    -----------------
Effective Date of the Schemes                              15 January 2010
 --------------------------------------------------    -----------------
Suspension of the Company's shares from trading  on ASX    15 January 2010
 --------------------------------------------------    -----------------
Unilife Corporation CDIs commence trading on ASX  on a
 deferred settlement basis                                18  January 2010
--------------------------------------------------    -----------------
Record Date for the Schemes                                22 January 2010
 --------------------------------------------------    -----------------
Implementation Date for the Schemes                        27 January 2010
 --------------------------------------------------    -----------------
Despatch of holding statements and transmittal  letters    1 February 2010
 --------------------------------------------------    -----------------
CDIs commence trading on normal T+3 basis                  2 February 2010
 --------------------------------------------------    -----------------
Expected commencement date for listing on  NASDAQ         10 February 2010
                                                          (subject to  SEC
                                                         review  of Form 10
                                                          and approval of
                                                          NASDAQ listing
                                                          application)
 --------------------------------------------------    -----------------
All dates and times are indicative only and are  subject to change.
All dates and times are Australian Eastern  Daylight Time
 
About Unilife
 
Unilife Medical  Solutions Ltd. is an ISO 13485 certified company that designs, develops  and supplies innovative safety medical devices. Listed on the Australian  Securities Exchange (ASX: UNI) since 2002, Unilife has FDA-registered  manufacturing facilities in the US State of Pennsylvania and a  proprietary portfolio of clinical and prefilled safety syringes designed  for use within healthcare and pharmaceutical markets.
 
 Shareholder / Analyst Enquiries:
Australia
Jeff Carter
 Phone: + 61 2 8346 6500
United States
Stuart Fine
Phone: +  1 908 469 1788

12.02.2010 13:32
www.finanznachrichten.de/...declares-form-10-effective-008.htm

Unilife Corporation to Commence Trading on the NASDAQ Global Market / SEC DECLARES FORM 10 EFFECTIVE

LEWISBERRY, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Unilife Corporation (Company) today announced that the US Securities and Exchange Commission (SEC) declared the Company's Form 10 registration statement effective, clearing the path for Unilife Corporation's listing on the NASDAQ.

The Company expects trading of Unilife Corporation common stock to commence on NASDAQ on or around February 16, 2010 under the ticker "UNIS".

Alan Shortall, CEO of Unilife, stated, "I would like to thank the Unilife team for the completion of this significant corporate milestone. In particular, I wish to note the important contribution made by the Unilife Finance department, and our Australian and US legal representatives, DLA Phillips Fox and DLA Piper who worked tirelessly to achieve this approval within our projected timeframe.

"Despite severe weather conditions in the eastern portion of the US that caused a shutdown of all Federal Government offices in Washington, DC, and restricted operations in both Pennsylvania and New York City, our team has been able to work co-operatively to complete the work necessary to achieve this result. I must compliment the Unilife team and our advisors for an outstanding effort."

The Company also wishes to advise that by the time trading of Unilife common stock commences on NASDAQ, it will have published on its website (www.unilife.com/) a list of Frequently Asked Questions (FAQs) to support shareholders wishing to trade on either the ASX or NASDAQ. The Company has also now opened an Investor Hotline to assist with shareholder enquiries during this period. The enquiry line numbers are 1800 632 680 (Australia toll free), +1 866 496 5819 (US toll free) and or +61 2 8256 3394 (International).

About Unilife Corporation

Unilife Corporation are a US based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

Unilife's main product is the Unifill(TM) ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. The Company has a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill(TM) syringe and is funding an industrialization program for the product. In addition, Unilife has retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.

Investor Contacts (US): Todd Fromer / Garth Russell KCSA Strategic Communications + 1 212-682-6300

Unilife Corporation

CONTACT: Todd Fromer or Garth Russell, both of KCSA Strategic
Communications, +1-212-682-6300

Web Site: www.unilife.com/